Medical/Pharmaceuticals
Published in Annals of Oncology: Disitamab Vedotin Combined with PD-1 Inhibitor is a Promising Treatment for Locally Advanced or Metastatic Urothelial Carcinoma
YANTAI, China, Jan. 8, 2025 /PRNewswire/ -- On Janurary 7th, 2025, Annals of Oncology (IF: 56.7), a top oncology journal globally, published remarkable long-term follow-up results of a phase1b/2 clinical trial on Disitamab Vedotin (DV) (developed by Remegen Co., Ltd) combined with Toripalimab in ...
Clarivate Identifies Eleven Potential Blockbuster and Transformative Drugs in Annual Drugs to Watch Report
Anticipated advancements in obesity, oncology, gene therapy and other areas poised to revolutionize patient care LONDON, Jan. 8, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, today announced the release of the twelfth annualDrugs to Watc...
Renue by Science Launches Innovative Liposomal NAD+ Skincare Line, Renue Blue, Emphasizing Skin Wellness and Longevity
JACKSONVILLE, Fla., Jan. 8, 2025 /PRNewswire/ -- Renue by Science™, a global leader in NAD+ precursor supplements, is excited to announce the official launch of its highly anticipated skincare range, Renue Blue™. With a focus on skin longevity and holistic wellness, this revolutionary line featur...
Verismo Therapeutics Announces Strategic Partnership with IFLI to Support SynKIR™-310 Development in Follicular Lymphoma
* Verismo will receive up to $4.05 million USD in investments from the Institute for Follicular Lymphoma Innovation (IFLI). * The partnership with IFLI will accelerate the clinical development of SynKIR™-310 in Follicular Lymphoma (FL) by leveraging IFLI's expertise and network, expanding cli...
GORTEC Announces New Trial Success for Head and Neck Cancer Treatment
TOURS, France, Jan. 7, 2025 /PRNewswire/ -- GORTEC, known as Head and Neck Radiation Oncology Group, today announced that the randomized Phase 3 NIVOPOSTOP GORTEC 2018-01 trial evaluating nivolumab, Bristol Myers Squibb's anti-PD-1 therapy, as a post-operative treatment component for resected pa...
Concept Medical Announces Successful SIRONA Trial Results, Demonstrating Sirolimus-Coated Balloon as a Promising Alternative for PAD Treatment
TAMPA, Fla., Jan. 7, 2025 /PRNewswire/ -- Concept Medical Inc.
Eyebright Medical Receives NMPA Class III Certificate for its Phakic Intraocular Lens
HONG KONG, Jan. 7, 2025 /PRNewswire/ -- Eyebright Medical Technology (Beijing) Co., Ltd. ("Eyebright Medical", the "Company", Stock Code: 688050.SH, together with its subsidiaries collectively known as the "Group") is proud to announce that our Phakic intraocular lens, "Loong Crystal PR", has rec...
Weimai bags RMB200m in Series D funding to enhance tech-enabled, continuous healthcare services
The latest funding round will fuel Weimai's efforts to expand its full-cycle healthcare solutions, leveraging AI and digital tools to provide comprehensive care acrossChina HANGZHOU, China, Jan. 7, 2025 /PRNewswire/ -- Weimai, a leading provider of one-stop digital healthcare solutions inChina, ...
Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma
Back to media releases
Innovent to Participate and Present at the 43rd Annual J.P. Morgan Healthcare Conference
SAN FRANCISCO and SUZHOU, China, Jan. 6, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune,...
Episode Two "The Wisdom of the Shanghai School" of CMG's "China TCM Show" (Season 2) to air this weekend
BEIJING, Jan. 4, 2025 /PRNewswire/ -- The second episode of "China TCM Show" is set to air this weekend. Called "The Wisdom of the Shanghai School," the episode will broadcast at8 p.m. Beijing Time on January 4th, on CCTV-1, with a rebroadcast scheduled for6 p.m. on January 5th on CCTV-4. This s...
Innovent Announces Second New Drug Application of DOVBLERON ® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) was Approved by China's National Medical Products Administration
SAN FRANCISCO and SUZHOU, China, Jan. 3, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune,...
CathWorks Announces the Completion of Enrollment for Landmark ALL-RISE Randomized Controlled Trial
ALL-RISE Study Included Over 1,924 Patients in 59 Sites Across North America, Asia, Europe and the Middle East NEWPORT BEACH, Calif., Jan. 3, 2025 /PRNewswire/ -- CathWorks, a global leader in medical device digital health innovations, announced today the successful completion of enrollment of t...
PieX AI: Launching the World's First Personalized, On-device AI Pendant at CES 2025
NEW YORK, Jan. 2, 2025 /PRNewswire/ -- PieX AI
HKSH Symposium on Advances in Cancer Management 2024 Breakthroughs in Cancer Management
HONG KONG, Jan. 2, 2025 /PRNewswire/ -- HKSH Cancer Centre organised the sixth "HKSH Symposium on Advances in Cancer Management" ("The Symposium") which was held on12 December 2024 at the HKSH Eastern Building. With the theme "Breakthroughs in Cancer Management", the Symposium attracted approxima...
HEALTH IN YOUR HANDS
The Rise of Home Testing for a Safer Future with AwarerHOME™ KUALA LUMPUR, Malaysia, Jan. 2, 2025 /PRNewswire/ -- HIV remains one of the most pressing health issues globally, yet for many, the conversation around it is still surrounded by discomfort and stigma. Despite advances in treatment and ...
Innovent Enters into Exclusive Global License Agreement with Roche for Novel DLL3 Antibody Drug Conjugate
SAN FRANCISCO and SUZHOU, China, Jan. 2, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune,...
Brii Bio Announces Signing of Asset Purchase Agreements Acquiring BRII-179 IP Rights and Completed Patient Enrollment for ENRICH Study
Further secures Brii's rights in BRII-179 with full control of intellectual property, future manufacturing and supply Several combination treatment studies containing BRII-179 have quickly started to carry forward the Company's strategy for HBV functional cure DURHAM, N.C. and BEIJING, Dec. 31, ...
NOBLE Registry Update: TLX599-CDx PSMA SPECT Imaging of Prostate Cancer Published in EJNMMI Reports
MELBOURNE, Australia and BRUSSELS, Dec. 31, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) and the Brussels-based Oncidium foundation today announce that results for the NOBLE Registry of TLX599-CDx (99mTc-iPSMA) have been published in the European ...
Alphamab Oncology Announced Anti-HER2 Bispecific ADC JSKN003 Received Approval from CDE to Initiate a Phase III Clinical Study for Ovarian Cancer
SUZHOU, China, Dec. 27, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that anti-HER2 bispecific antibody-drug conjugate (ADC) JSKN003 has received approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) to initiate a Phase...
Week's Top Stories
Most Reposted
Visa returns as title sponsor for 2026 MAMA AWARDS; Visa Presale registration begins 13 October
[Picked up by 310 media titles]
2026-10-13 10:00Agoda and Emerging Travel Group Enter Strategic Partnership
[Picked up by 287 media titles]
2026-10-15 16:00Food & Hospitality Asia 2027 Redefining Excellence: The Premier Platform for Food & Beverage and Hospitality Innovation
[Picked up by 280 media titles]
2026-10-15 10:00Leading Asian DMC Discova to Attend ITB Asia 2026
[Picked up by 276 media titles]
2026-10-15 12:59New Asia Forum Targets US$30 Billion in Investment into the New Asia at Its Inaugural Edition in Bali
[Picked up by 275 media titles]
2026-10-09 13:21